Der er ingen prospektivt randomiserede sammenligninger mellem de to anbefalede metoder til mobilisering (filgrastim alene eller i kombination med myelosuppressiv kemoterapi) inden for samme patientpopulation.
There are no prospectively randomised comparisons of the two recommended mobilisation methods (filgrastim alone or in combination with myelosuppressive chemotherapy) within the same patient population.